RANIBIZUMAB intravitreal injection (Lucentis®) for choroidal neovascularisation - Pan Mersey APC Skip to main content Help with accessibility Skip to main navigation

RANIBIZUMAB intravitreal injection (Lucentis®) for choroidal neovascularisation

Last Updated: 27 September 2017

Body System: Eye

Red

The Pan Mersey Area Prescribing Committee recommends the prescribing of RANIBIZUMAB intravitreal injection (Lucentis®), by ophthalmologists only, for the treatment of visual impairment secondary to choroidal neovascularisation (CNV) in conditions not covered by NICE technology appraisals.